European Monoclonal Antibody Cancer Therapeutics Market

 


Availability: In stock

 

Regular Price: USD 3,950

Special Price USD 2,765

* Required Fields

Regular Price: USD 3,950

Special Price USD 2,765

PAY BY INVOICE

Be the first to review this product

Table of Contents

European Monoclonal Antibody Cancer Therapeutics Market, Executive SummaryMarket Overview and DefinitionsMarket Overview and DefinitionsMarket DriversMarket RestraintsThe Current Situation The Current Situation The Future of Monoclonal Antibodies in the Treatment of CancerThe Future of Monoclonal Antibodies in the Treatment of CancerGeographical TrendsCompetitive StructureConclusionsConclusionsEuropean Monoclonal Antibody Cancer Therapeutics Market, Industry Challenges in the Monoclonal Antibody Cancer Therapeutics MarketIndustry ChallengesClinical Trial IssuesRegistration IssuesSize of the TumourMouse Antibodies seen as ForeignCost RestrictionsMarket Engineering Research for the European Cancer Monoclonal Antibody Therapeutics MarketForecasts of the Total MarketMarket Overview and DefinitionsOverview—General Principles of Immunotoxin TherapyMonoclonal Antibodies and CancerTrends by Product TypeDefinitions of TermsEuropean Monoclonal Antibody Cancer Therapeutics Market, Research and Development in Monoclonal Antibodies for CancerIntroductionIntroductionHaematological MalignanciesLeukaemiaLymphomaCompetitors Phase II to Launch MAbs in EuropeCompetitors Phase II Studies to Launch Haematological Malignancies in EuropeSolid TumoursOverviewBreast CancerOvarian CancerColorectal CancerHead and Neck CancerProstate CancerCompetitors Phase II Studies to Launch Solid Tumours in EuropeEuropean Monoclonal Antibody Cancer Therapeutics Market, Epidemiology and the Potential Treatable PopulationsForecast AssumptionsForecast AssumptionsHaematological CancersIntroductionPotential Treatable Population with Acute Myelogenous LeukaemiaPotential Treatable Population with Chronic Lymphocytic LeukaemiaPotential Treatable Population with Non-Hodgkins LymphomaSolid TumoursBreast Cancer Ovarian CancerHead and Neck CancerColorectal CancerProstate CancerMarket Engineering Research for the European Monoclonal Antibody Cancer Therapeutics MarketMarket Overview Market Overview Market Engineering Research Measurement SystemMarket IssuesMarket Drivers and Restraints Forecast Assumptions Pricing IssuesReimbursement Issues in EuropeProjected Revenue and Revenue Growth Rates 1997–2006Projected Revenue and Revenue Growth Rates 1997–2006Competitive AnalysisCompetitive Structure Competitive SituationMarket Engineering Research for the European Monoclonal Antibody Market for Haematological Cancers Market Overview and DefinitionsMarket Overview and DefinitionsMarket Engineering Research Measurement SystemTotal Haematological Market ForecastMarket Engineering Revenue Forecasts by Product (2000–2006)MabThera BexxarZevalinLymphocideCampathMylotargSMART M195The Competitive SituationThe Competitive SituationCompetitive StructureCompetitive Market Share Analysis - Trends and DiscussionMarket Engineering Revenues for the European Market for Monoclonal Antibodies in Solid TumoursTotal Market Overview and DefinitionsTotal Market Overview and DefinitionsMarket Engineering Research Measurement SystemTotal Solid Tumour Market ForecastMarket Engineering Revenue Forecasts by Product(2000–2006)HerceptinTheragynOvaRexCetuximab: IMC-C225IDM-1 (MDX-210)MDX-210 Bevacizumab (RhuMAb-VEGF)The Competitive SituationThe Competitive SituationCompetitive StructureCompetitive Market Share Analysis - Trends and DiscussionEuropean Monoclonal Antibody Cancer Therapeutics Market, Company ProfilesCompetitor OverviewsMedImmune CorixiaImmuno-Designed-Molecules/MedarexAntisomaRoche/GenentechGenentech/IDECImClone Systems/MerckAltaRex/Dompe BiotechCelltech/Wyeth-AyerstSchering ImmunomedicsPeregrine Pharmaceuticals Financial HealthcheckEuropean Monoclonal Antibody Cancer Therapeutics Market, Strategic Recommendations for the Monoclonal Antibody Cancer Therapeutics MarketBiotech and "Big Pharma" AlliancesBiotech and "Big Pharma" AlliancesFocus within a Certain Cancer GroupFocus within a Certain Cancer GroupAggressive Marketing CampaignsAggressive Marketing CampaignsInvolvement within Technology Rather than Drug TherapyInvolvement within Technology Rather than Drug TherapyPharmacoeconomic Analysis Pharmacoeconomic Analysis Working Together to Grow Industry Working Together to Grow Industry European Monoclonal Antibody Cancer Therapeutics Market, Database of Key Industry ParticipantsDatabase of Key Industry ParticipantsDatabase of Key Industry ParticipantsEuropean Monoclonal Antibody Cancer Therapeutics Market, Decision Support DatabaseCancer IncidenceIncidence of Breast CancerIncidence of Colorectal CancerIncidence of Lung CancerIncidence of Prostrate CancerCancer MortalityMortality due to Breast CancerMortality due to Lung CancerMortality due to Prostrate Cancer




Related Research

Release Date : 25-Jul-17

Region : Europe

Release Date : 12-Jul-17

Region : Europe

Release Date : 06-Jul-17

Region : Europe

Release Date : 05-Jul-17

Region : Europe

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.